AlphaLens
Research
研报OverweightTP $6.00005月14日 · Morgan Stanley

Reckitt Benckiser: Risk Reward Update

中文EN⚠ quality lint: see notes

Reckitt Benckiser: Attractive Risk/Reward as Valuation De-Rates Despite Resilient Earnings

Core Thesis

Reckitt Benckiser (RKT.L) presents a favorable risk/reward at current levels, trading at ~13.7x CY26 P/E (a 15% discount to European Staples) while the core business delivers mid-single-digit organic growth and EPS compounding. The stock retains Overweight rating with a 5,800p price target, offering ~28% upside. Near-term top-line growth has been trimmed, but FX tailwinds and margin discipline leave EPS estimates broadly unchanged. The key unresolved overhang—Enfamil litigation—is already discounted, and any clearing event could catalyze a re-rating. The market is pricing in a low-probability outcome for Mead Johnson that understates embedded optionality.

Key Changes: Softer OSG, But Earnings Intact

The FY26 group organic sales growth (OSG) estimate is lowered from +3.6% to +3.4%, with Core Reckitt OSG now at +3.8% (low end of 4-5% target). This reflects a slower H1 and an assumption that price increases in H2 to offset commodity inflation may compress volumes. However, margin expansion is narrowed to only 12bps (from 55bps previously) due to commodity cost headwinds. Yet, less adverse FX assumptions mean that EBIT and EPS are unchanged (FY26e EPS 334.6p vs 334.8p prior). The net effect: earnings power is intact, but growth quality has shifted from volume-led to price-led.

Evidence Chain: Where the Upside Comes From

1. Valuation floor is visible. At 4,546p, the stock trades at ~13.7x CY26 P/E, a 15% discount to EU Staples. The analyst applies 16.5x (in-line with sector) to derive a 5,800p target. The DCF (WACC 7.8%, TG +2.5%, terminal margin ~26.5%) yields £62, consistent with the target. The bull case at 7,500p assumes sustained 5% LFL growth, 50bps margin expansion, and favourable litigation resolution plus Mead Johnson sale at the high end of valuation (£1bn-3bn). That implies ~65% upside.

2. Market share opportunity in SE Asia/India. Scanner data and competitor commentary suggest local players in these key territories face supply chain constraints, potentially benefiting Reckitt in Germ Protection and Household Care. This could offset some volume softness from pricing.

3. Earnings trajectory improves from FY27. After an estimated MSD% EPS decline in FY26 (stranded costs from Essential Home disposal and higher depreciation), EPS is projected to grow at ~+6% CAGR from FY27, supported by buybacks. At current multiples, the market is not paying for that recovery.

4. Mead Johnson optionality is unappreciated. The base case assumes a mid-point litigation liability and a moderate disposal outcome. If litigation clears favourably or the sale exceeds expectations, the stock could re-rate to a premium (30% above Staples) on superior FCF and ROIC.

Key Risks

  • Enfamil litigation (neurodevelopmental claims): The worst-case scenario (bear case) assumes a $2.7bn liability, pushing the stock to 3,900p (~12.4x CY26 P/E, 25% discount to Staples). Current options-implied probability of the stock falling below 3,900p in 12 months is ~24%, reflecting meaningful tail risk.
  • Commodity inflation / pricing volume trade-off: If H2 price increases destroy more volume than modelled, OSG could slip further, and margin expansion may not materialise.
  • Mead Johnson disposal delay or poor execution: The process has not yet commenced; a weak sale outcome would remove a catalyst and keep balance sheet deleveraging slow.
  • FX volatility: GBP strength would reduce reported earnings, although current estimates already assume less adverse FX.
  • Competition in OTC: Seasonal cough/cold demand is unpredictable and margins in that segment are above group average; a weak season could drag margins.

Valuation and Trade Implications

At 4,546p, the risk/reward asymmetry is clear: ~28% upside to base case (5,800p) vs ~14% downside to bear case (3,900p). The options-implied probability of reaching 5,800p or above in 12 months is only ~12%, suggesting the market is overly pessimistic. The Overweight rating is justified by a low valuation, a clear self-help story (cost savings, portfolio simplification), and a potential special situation (litigation resolution, MJ sale). The primary catalyst for re-rating would be any positive news on Enfamil or a clearer path to Mead Johnson monetisation, but even in the absence of those, the current price embeds little growth premium.

Recommendation: Accumulate. The stock offers a reasonable margin of safety even in the bear case, and the base case provides double-digit upside from unchanged earnings. The primary risk is litigation, but it is partially discounted. The downside is limited to ~14% if the worst materialises, while the base case and bull case offer asymmetric returns.